Recombinant Exosome Membrane-Bound EGF Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Recombinant human epidermal growth factor (EGF) is biologically and physicochemically unstable, leading to low wound healing efficacy when applied directly to wounds, as it degrades quickly and is inhomogeneous, causing allergic reactions and loss of biological activity.

Innovation Solution

Development of recombinant exosomes with membrane-bound EGF proteins, which are more stable and effectively deliver EGF to wound sites, promoting epithelial cell proliferation and wound healing.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If recombinant human EGF is applied directly to wound sites, then epithelial cell differentiation is promoted, but wound healing effect is insufficient due to rapid degradation and loss of biological activity

Engineering Contradiction:

Improvewound healing effectVSAvoidbiological stability of EGF

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent uses exosomes as intermediary carriers to deliver EGF to wound sites. The exosome membrane structure protects the EGF protein from rapid degradation while maintaining its biological activity. The exosome acts as a protective vehicle that transports EGF to the target site without immediate degradation, thus resolving the contradiction between stability and therapeutic effect.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the physical and chemical state of EGF from a free protein to a membrane-bound form incorporated within exosomes. This parameter change (from soluble protein to encapsulated structure) significantly improves the half-life and stability of EGF in vivo, allowing it to maintain biological activity for extended periods at wound sites.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If recombinant human EGF is stored for long periods, then availability for treatment is improved, but physicochemical homogeneity is lost and degradation products cause allergies

Engineering Contradiction:

Improveavailability of EGF for treatmentVSAvoidallergic reactions from degradation products

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

Exosomes serve as stable intermediary carriers that protect EGF from degradation during storage and administration. The exosome membrane structure acts as a protective barrier that prevents EGF from breaking down into allergenic degradation products, while still allowing the therapeutic protein to reach the target site effectively.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Duration of action of moving object

If EGF is applied to treat wounds, then cell proliferation is stimulated, but the short half-life prevents sustained therapeutic effect

Engineering Contradiction:

Improveduration of EGF activity at wound siteVSAvoidtherapeutic effect consistency

Core Design Contradiction:

Duration of action of moving objectVSReliability

Solution Approach 1:

The exosome serves as a long-lasting intermediary carrier that releases EGF gradually at the wound site. This extended release mechanism increases the duration of therapeutic action compared to direct EGF application, as the exosome structure protects and sustains the protein's biological activity over time.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The exosome-based delivery system enables continuous or prolonged exposure of wound cells to active EGF by releasing the protein gradually from the exosome structure. This continuous action maintains therapeutic levels of EGF at the wound site for extended periods, ensuring consistent and reliable healing effects.

Inventive Principle:

Principle #20Continuity of useful action

Data Source

PatentUS20230226215A1Novel recombinant exosome and use thereof

Publication Date: 2023.07.20 REONEBIO

AI summary

The present invention provides a recombinant exosome comprising a membrane-bound EGF protein on the surface of the recombinant exosome and provides a use of the recombinant exosome.